Empowering European hospital pharmacists in the face of heart failure

Lise Defieuw,Julie Hias,Fatma Karapinar-Carkıt,Paul Forsyth,Lorenz Roger Van der Linden

DOI: https://doi.org/10.1136/ejhpharm-2023-004068

2024-06-22

European Journal of Hospital Pharmacy: Science and Practice

Abstract:European hospital pharmacists can play a crucial role in the care of heart failure (HF). In this editorial, we highlight that our profession is well suited for the task, and provide evidence that pharmacist support is highly valued in HF management.1 2 HF is a high-risk condition with growing prevalence, and is predominantly treated with pharmacotherapy. In the developed world, it currently affects 1–2% of the population, with a notable age dependency.3 Among individuals aged 70 years and older, the prevalence of HF exceeds 10%. This progressive condition, characterised by a mismatch between the heart's ability to meet the body's demands, causes typical symptoms, such as fatigue and fluid retention, which significantly impair the patient's quality of life. HF leads to considerable morbidity and mortality.3 4 Even in so-called 'stable' chronic HF, patients still endure a high residual HF burden. For example, the recent Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) study revealed a staggering 7.9% all-cause mortality at 1 year among ambulatory chronic HF patients who received dapagliflozin. The risks are even greater for those who experienced an acute HF episode, constituting up to 25% of all HF patients. This high-risk group faces a 90-day mortality of up to 15% after hospital discharge, with 30% experiencing readmission during the same period.3 Healthcare utilisation in HF is greatly affected by the numerous readmissions, making HF one of the leading ... Correspondence to Professor Lorenz Roger Van der Linden, Hospital Pharmacy Department, UZ Leuven, Leuven, Flanders, Belgium; lorenz.vanderlinden{at}uzleuven.be